When Is It Safe to Have the Skin Removed?

Large weight loss leaves skin that does not retract, and body contouring surgery is the only thing that removes it. Timing matters, because weight that changes after the operation distorts the result. A systematic review of 12 studies and 13,947 patients puts the plateau at 53.0 ± 8.2 weeks, at around 16% weight loss.^[1] The more consequential finding is about what happens if you stop the drug afterward.

The timing answer

The reviewers defined a plateau as at least one month during which weight loss was under 3%, and calculated when that arrived across every eligible trial and prospective study.

Those last two rows are the useful part for a surgical decision. At the plateau, someone is within about two percentage points of the most weight they will lose on the drug and within one point of where they will finish. In other words, the plateau really is close to the end of the curve, so operating there is operating on close to a final body.

Why this says 53 weeks when we said 24 to 36

That is a cleaner demonstration than we could have constructed. The earlier article’s whole point was that “plateau” is a defined threshold rather than an observed event, and that the definition governs the answer — what a plateau actually means. Two competent reviews of the same phenomenon differ by half a year because they drew the line in different places.

For a surgical decision the stricter definition is the appropriate one. A tolerance of 5% over three months is fine for reassuring someone that their drug is still working; it is not fine for deciding that a body has stopped changing shape.

The variable that matters more than the date

Two of the included studies followed people after they stopped the drug. Weight recurrence — defined as regaining at least a quarter of what was lost — appeared at 12 weeks in one and 24 weeks in the other. By the end of observation, participants had regained 62.7% and 74.3% of their greatest on-treatment weight loss.

Skin removed at one body size, and then a body that changes underneath it.

That regain figure rests on two studies, which is thin, and it is consistent with the withdrawal trials we cover in what happens when you stop. The direction is not in doubt even if the size is imprecise.

It follows that the cost of the drug is part of the cost of the surgery. Someone planning contouring should be planning to afford continued treatment, and the evidence on maintenance alternatives — a lower labeled dose, or handing over to another agent — is in the maintenance trial and the oral handover.

What this review does not settle

• It is timing evidence, not surgical outcome evidence. It calculates when weight stops moving, not whether operating then produces better results — which would need a trial nobody has run.
• Fifty-three weeks is a pooled average with a standard deviation of eight, so individuals vary by months in both directions.
• It concerns semaglutide. Tirzepatide produces more weight loss and may plateau differently.
• Nothing here addresses surgical risk on these drugs, including the anesthesia considerations covered in before endoscopy and surgery.

Timing is a judgment a surgeon makes about a particular person. This is the published evidence they would be drawing on, and the part most worth bringing to that conversation is the second half — not when the weight stops, but what happens to it afterward.